EP. 2 Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPCByHannah ClarkeAugust 10th 2026
The AUA Clinically Localized Prostate Cancer guideline: FAQs for urologistsByHannah ClarkeAugust 10th 2026
Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPCByHannah ClarkeAugust 8th 2026
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancerByNeil H. Baum, MD,Abraham Morgentaler, MDAugust 6th 2026